OVERVIEW
In many neurological diseases, the absence of an identified neurotransmitter, enzyme, cofactor, or trophic factor has been implicated totally or in part for the condition's manifestations (e.g., Parkinsonism, Huntington's disease, Alzheimer's disease, lysosomal storage disorders, and other neurogenetic diseases or inborn errors of metabolism). Pharmacologic agents administered systemically, the traditional therapy for many such disorders, not only often have erratic effects and transient efficacy, but frequently produce undesirable side effects. For various neurogenetic and inherited metabolic diseases, in which a single gene product has been found deleted or defective (e.g., Gaucher's disease, mucopolysaccharidosis, frucocidosis, metachromatic leukodystrophy), bone marrow transplantation (BMT) and enzyme replacement have been successful in reversing hematologic, skeletal, and visceral manifestations, but have been disappointing in reversing or forestalling damage to the central nervous system (CNS). This limitation is presumably due to restrictions imposed by the blood-brain barrier (BBB) to entry of therapeutic molecules supplied peripherally either directly or through genetically engineered somatic cells (reviewed in Desnick, 1991). Furthermore, BMT entails irradiation which may be inimical to developing CNS. Dietary manipulations have also proven less than satisfactory. The delivery of missing gene products directly to the CNS might circumvent these problems. In other types of neurologic diseases, specific neural cell types or circuits degenerate. These losses may be due to deficiencies intrinsic to the diseased cell or to a milieu plagued by an insufficiency of certain trophic factors or an overabundance of toxic substances.
''Gene therapy'' is defined most broadly as providing a gene whose product can alleviate the consequences of a defective gene, cell, or organ (reviewed in Snyder & Fisher, 1996) . The minimal requirements for such therapy are simply the absence of undesirable side effects and sustained production of the gene product. Gene transfer into the CNS may be achieved by the direct delivery of exogenous genetic material to the host's own neural tissue. The advantages and limitations of various vectors have been extensively reviewed (Mulligan, 1993; Fisher & Ray, 1994; Friedmann 1992 Friedmann , 1994 Suhr & Gage, 1993; Hodgson, 1995; Kaplitt & Loewy, 1995) . Alternatively, genes may be imported into the host CNS by the implantation of genetically modified donor cells which can reside within the brain and make exogenous gene products accessible to the host's neural tissue (Fig. 1) . In the first approach, the investigator's challenge is to design a vector which can efficiently, yet selectively and safely, transduce a gene to a very specialized, usually heterogeneous, group of host neural cells, some of which are mitotic and some of which are not, some of one cell type and some of another, some old and some young. In the neural transplantation strategy, because genetic manipulation occurs ex vivo, an investigator is somewhat freer to orchestrate which vector is best suited for which cell type (often a homogeneous donor population) in the transduction of a particular gene of interest. The challenge then comes in efficiently and safely introducing those modified cells into the desired re-1 To whom correspondence should be addressed. 69-102 (1997) Article No. NB970138 
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